Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for Codeine Sulfate by Hikma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Hikma7 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:33:11 PM

Assessment confidence: 50% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of Hikma's supplemental application for Codeine Sulfate is a significant regulatory milestone that could strengthen Hikma's competitive position in the opioid pain management market. Pharma strategy teams should evaluate potential shifts in market dynamics and prepare for competitive responses from other manufacturers. Regulatory context from FDA (FDA AP — CODEINE SULFATE (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact on Hikma's market share and consider competitive responses from other opioid manufacturers. The strongest clinical anchor is Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 4 regulatory and 2 competitive items passed relevance filtering for Hikma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This acceptance may enhance Hikma's position in the pain management market, particularly in the opioid segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CODEINE SULFATE (SUPPL) (FDA). Entity match (hikma). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final decision will determine the extent of compliance and market readiness for Hikma's product.

Key Risks

Elevated medium regulatory exposure for Hikma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Hikma could capture additional market share in the opioid segment, impacting revenue streams for competitors. This could lead to strategic adjustments in pricing and marketing strategies across the sector.
Portfolio teams should assess the potential impact on Hikma's market share and consider competitive responses from other opioid manufacturers.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's final decision and any subsequent market reactions.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CODEINE SULFATE (SUPPL)
FDAmedium relevance
Entity match (hikma)
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAmedium relevance
Entity match (hikma)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAmedium relevance
Entity match (hikma)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAmedium relevance
Entity match (hikma)
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — FIORICET W/ CODEINE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — MORPHINE SULFATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
Codeine Sulfate

Commercial impact

medium

If approved, Hikma could capture additional market share in the opioid segment, impacting revenue streams for competitors. This could lead to strategic adjustments in pricing and marketing strategies across the sector.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final decision will determine the extent of compliance and market readiness for Hikma's product.

What to watch

Monitor the timeline for the FDA's final decision and any subsequent market reactions.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.